Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906995 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Nicotine Sublingual Tablets Versus Nicorette Lozenge in Healthy Smokers
A Phase 1 study, sponsored by Friends Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02906995 is a Phase 1 study that has completed, run by Friends Research Institute. The registered enrollment target is 24 participants.
The verdict
NCT02906995, a Phase 1 study, has completed, sponsored by Friends Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to compare two different dosage forms from which nicotine is released and absorbed into the bloodstream.
Interventions
- DRUG Sublingual tablet 4 mg versus Nicorette Lozenge 4mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906995
The ClinicalTrials.gov registry entry for NCT02906995 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Friends Research Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sublingual tablet 4 mg versus Nicorette Lozenge 4mg is the first listed.
NCT02906995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906995 about?
NCT02906995 is a clinical study titled "Pharmacokinetics of Nicotine Sublingual Tablets Versus Nicorette Lozenge in Healthy Smokers". The purpose of the study is to compare two different dosage forms from which nicotine is released and absorbed into the bloodstream.
What is the current status of trial NCT02906995?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-05-25. Estimated completion is 2017-11-27.
What interventions are being tested in trial NCT02906995?
The interventions under investigation include: Sublingual tablet 4 mg versus Nicorette Lozenge 4mg (DRUG).
Who is sponsoring clinical trial NCT02906995?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.